VICTORIA, BC, Sept. 6,
2023 /CNW/ - Eupraxia Pharmaceuticals Inc.
("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage
biotechnology company with an innovative drug delivery technology,
today announced that it will present a poster and an oral
presentation at PAINWeek 2023, a national conference on pain for
healthcare professionals, taking place on September 5-8, 2023, in Las Vegas, NV.
"PAINWeek is the largest U.S. pain conference for frontline
clinicians and a high-profile opportunity for Eupraxia to present
data from our Phase 2b clinical trial
of EP-104IAR to an audience of practitioners in the pain
space," said Dr. James Helliwell,
CEO of Eupraxia. "We believe these previously disclosed Phase
2b results, which are integral to our
PAINWeek presentation, demonstrate that we are developing a product
candidate with the potential for prolonged duration, and a
compelling safety profile that may allow for repeat and bilateral
dosing in patients experiencing pain due to osteoarthritis of the
knee."
Poster Title: EP-104IAR (Long-Acting Intra-Articular
Injection of Fluticasone Propionate): Results from a Phase 2
Randomized, Double-blind, Vehicle-Controlled Trial in 318 Subjects
with Knee Osteoarthritis
Session Title: SIS-17 Scientific Abstracts (Oral
Presentations)
Abstract Number: PW10823
Presentation Date and Time: Friday, September 8,
2023, 10:30-11:20 a.m. ET via the
PAINWeek website at:
https://www.painweek.org/
The poster presentation will also be available on Eupraxia's
website on September 8, 2023, at:
https://eupraxiapharma.com/our-science/clinical-trials-and-publications/default.aspx
About Eupraxia Pharmaceuticals
Inc.
Eupraxia is a clinical-stage biotechnology company focused on
the development of locally delivered, extended-release products
that have the potential to address therapeutic areas with high
unmet medical need. The Company strives to provide improved patient
benefit and has developed technology that delivers targeted,
long-lasting activity with fewer side effects.
Eupraxia's lead product candidate, EP-104IAR, recently completed
a Phase 2b clinical trial for the
treatment of pain due to osteoarthritis of the knee. EP-104IAR met
its primary endpoint and three of the four secondary endpoints. The
EP-104 platform has expanded into gastrointestinal disease and has
dosed patients in a Phase 1b/2a
program to treat eosinophilic esophagitis. Eupraxia is also
developing a pipeline of later- and earlier-stage long-acting
formulations. Potential pipeline indications include candidates for
both other inflammatory joint indications and oncology, each
designed to improve on the activity and tolerability of currently
approved drugs. For further details about Eupraxia, please visit
the Company's website at: www.eupraxiapharma.com.
Forward-Looking
Statements
This news release includes forward-looking statements and
forward-looking information within the meaning of Canadian
securities laws. Often, but not always, forward-looking information
can be identified by the use of words such as "plans", "is
expected", "expects", "scheduled", "intends", "contemplates",
"anticipates", "believes", "proposes" or variations (including
negative and grammatical variations) of such words and phrases, or
state that certain actions, events or results "may", "could",
"would", "might" or "will" be taken, occur or be achieved.
Forward-looking statements in this news release include statements
regarding the Company's business strategies and objectives,
including current and future plans and opportunities, expectations
and intentions; statements regarding the Company's ongoing clinical
trials and pipeline development; the ability of the Company to
execute on its business strategy; the Company's planned poster
presentation at PAINWeek 2023; the potential of Eupraxia's product
candidates; the Company's expectations regarding its product
designs, including with respect to potential benefits, targeted
shelf life, storage, ease of integration, duration, tolerability,
effectiveness and safety; the results gathered from studies of
Eupraxia's product candidates; the potential for the Company's
technology to impact the drug delivery process; the competitive
advantages of the Company's technology; the benefits to patients
from the Company's drug platforms; and the translation of the
Company's technologies and expansion of its offerings into clinical
applications.
Such statements and information are based on the current
expectations of Eupraxia's management, and are based on
assumptions, including but not limited to: future research and
development plans for the Company proceeding substantially as
currently envisioned; industry growth trends, including with
respect to projected and actual industry sales; the Company's
ability to obtain positive results from the Company's research and
development activities, including clinical trials; and the
Company's ability to protect patents and proprietary rights.
Although Eupraxia's management believes that the assumptions
underlying these statements and information are reasonable, they
may prove to be incorrect. The forward-looking events and
circumstances discussed in this news release may not occur by
certain dates or at all and could differ materially as a result of
known and unknown risk factors and uncertainties affecting
Eupraxia, including, but not limited to: the Company's limited
operating history; the Company's novel technology with uncertain
market acceptance; if the Company breaches any of the agreements
under which it licenses rights to its product candidates or
technology from third parties, the Company could lose license
rights that are important to its business; the Company's current
license agreement may not provide an adequate remedy for its breach
by the licensor; the Company's technology may not be successful for
its intended use; the Company's future technology will require
regulatory approval, which is costly and the Company may not be
able to obtain it; the Company may fail to obtain regulatory
approvals or only obtain approvals for limited uses or indications;
the Company's clinical trials may fail to demonstrate adequately
the safety and efficacy of its product candidates at any stage of
clinical development; the Company may be required to suspend or
discontinue clinical trials due to side effects or other safety
risks; the Company completely relies on third parties to provide
supplies and inputs required for its products and services; the
Company relies on external contract research organizations to
provide clinical and non-clinical research services; the Company
may not be able to successfully execute its business strategy; the
Company will require additional financing, which may not be
available; any therapeutics the Company develops will be subject to
extensive, lengthy and uncertain regulatory requirements, which
could adversely affect the Company's ability to obtain regulatory
approval in a timely manner, or at all; the impact of the COVID-19
pandemic on the Company's operations; and other risks and
uncertainties described in more detail in Eupraxia's public filings
on SEDAR+ (www.sedarplus.ca). Although Eupraxia has attempted to
identify important factors that could cause actual actions, events
or results to differ materially from those described in
forward-looking statements and information, there may be other
factors that cause actions, events or results to differ from those
anticipated, estimated or intended. No forward-looking statement or
information can be guaranteed. Except as required by applicable
securities laws, forward-looking statements and information speak
only as of the date on which they are made and Eupraxia undertakes
no obligation to publicly update or revise any forward-looking
statement or information, whether as a result of new information,
future events or otherwise.
SOURCE Eupraxia Pharmaceuticals Inc.